Vectibix, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

Vectibix

Panitumumab

Prescription required

$760.00

100mg/20ml · 100 vial

BrandBranded medicine· By Amgen

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningDermatologic toxicity

Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy.

Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy.

Read this with the rest of the clinical information

About Vectibix

Overview

Vectibix contains panitumumab, a monoclonal antibody given into a vein to treat certain types of metastatic colorectal cancer in adults. For cancers without KRAS or NRAS mutations, it is used with FOLFOX chemotherapy as initial treatment, or alone after the cancer has progressed following specified chemotherapy treatments. For cancers with a KRAS G12C mutation confirmed by an FDA-approved test, it is used with sotorasib after prior chemotherapy. It works by blocking EGFR, a protein on cells that helps send signals for cell growth and survival.

What it treats

- Metastatic colorectal cancer in adults whose tumours have no mutations in either KRAS or NRAS (wild-type RAS), confirmed by an FDA-approved test. Used with FOLFOX chemotherapy as first-line treatment, or alone if the cancer has progressed after fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy. - Metastatic colorectal cancer in adults whose tumours have a KRAS G12C mutation, confirmed by an FDA-approved test. Used with sotorasib after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Not indicated when RAS mutation status is unknown, or for RAS-mutant metastatic colorectal cancer except with sotorasib for the KRAS G12C-mutated type.

Safety information

Side effects

Common side effects of Vectibix used alone include skin rash, inflammation around the nails, tiredness, nausea and diarrhea. When used with FOLFOX chemotherapy, common effects also include mouth sores, inflammation of moist body linings, weakness, loss of appetite, low magnesium or potassium levels, acne-like rash, itching and dry skin. With sotorasib, common effects include rash, dry skin, diarrhea, mouth sores, tiredness, and muscle or bone pain. Contact a doctor promptly for severe skin or soft tissue reactions, reactions during an infusion, or new or worsening eye problems. Serious eye problems include inflammation, ulceration or perforation of the cornea. Other serious risks include acute kidney failure, lung inflammation or scarring, and changes in blood mineral levels. Blood tests are needed to monitor these levels. Severe or life-threatening reactions may require treatment to be interrupted or stopped. Vectibix can increase sensitivity to sunlight; limit sun exposure. In patients whose metastatic colorectal cancer has RAS mutations, Vectibix used alone or with oxaliplatin-based chemotherapy may increase tumor progression or the risk of death, or provide no benefit. Combining Vectibix with bevacizumab and chemotherapy increases the risk of death and toxicity. Vectibix can harm an unborn baby. Use effective contraception during treatment and for 2 months after the last dose.

FDA boxed warning

Dermatologic toxicity

Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy.

Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Severe skin rash or other severe skin problems. - New or worsening eye inflammation, especially affecting the clear front surface of the eye. - Severe diarrhea.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Using Vectibix

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VECTIBIX (PANITUMUMAB) SOLUTION [AMGEN, INC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines